Notably, we show that, despite the higher immunogenicity of induced dMMR (idMMR) neuroblastoma tumors, anti-programmed cell death 1 (PD1) therapy does not elicit a therapeutic effect against such tumors similar to adult malignancies treated with this treatment strategy.11 This evidence concerns the gene PDCD1 and neuroblastoma.